Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test
June 15, 2021 08:00 ET
|
Scipher Medicine Corporation
Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in an independent validation cohort PrismRA demonstrates a more...
Scipher Applies Spectra™ Platform to Discover Drugs Targeting Autoimmune Patients Refractory to Existing Therapies
May 04, 2021 08:00 ET
|
Scipher Medicine Corporation
- Leverages large genomic database from Scipher’s testing business.- Proven Spectra™ platform brings precision therapeutics to autoimmune diseases.- Program commercialized through pharma partnerships....
Scipher Medicine Announces $82 Million Financing
March 24, 2021 08:00 ET
|
Scipher Medicine Corporation
-aMoon and Northpond Ventures led the round.-Additional investors include Echo Health Ventures, Khosla Ventures and Alumni Ventures.-Financing will support commercialization of precision medicine...
WellDyne Partners with Scipher Medicine to Improve Patient Outcomes and Lower Costs for Rheumatoid Arthritis Care
February 11, 2021 08:00 ET
|
Scipher Medicine Corporation
WALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced a partnership with WellDyne, a...